Tags

Type your tag names separated by a space and hit enter

A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
Int Urol Nephrol. 2014 Jan; 46(1):113-9.IU

Abstract

BACKGROUND

Treatment of secondary hyperparathyroidism (SHPT) is important in management of patients with end-stage renal disease on hemodialysis (HD). Calcimimetic agent, cinacalcet provides an option for control of SHPT in patients who fail traditional therapy. It may not have optimal results in non-compliant patients. To enhance compliance, we evaluated effectiveness of post-dialysis dosing of cinacalcet (group AD) as compared to daily home administration (group D) in a prospective randomized trial of HD patients with refractory SHPT.

METHODS

After 2-week run-in phase, patients were randomly assigned to two treatment groups. In group AD (N = 12), patients were administered cinacalcet on the day of dialysis (3 times/week) by dialysis staff, while in control group D (N = 11), cinacalcet was prescribed daily to be taken by patients at home. Intact parathyroid hormone (i-PTH), serum calcium, phosphorus, and alkaline phosphatase were followed for 16 weeks and compared to baseline in both groups. Data were analyzed using between-groups linear regression for repeated measures.

RESULTS

No significant decline in i-PTH occurred in group AD at 16 weeks as compared to a significant drop in group D (p = 0.006). However, subgroup analysis showed effectiveness of post-dialysis dosing in patients with less severe SHPT (p = 0.04).

CONCLUSION

Although daily dosing overall was more effective for treatment of SHPT, dialysis dosing was effective in patients with less severe SHPT. This warrants a larger study considering the limitations of this pilot trial. In the meantime, dialysis dosing can be considered in non-compliant patients with less severe SHPT.

Authors+Show Affiliations

Tawam Hospital in Affiliation with Johns Hopkins, Al Ain, Abu Dhabhi, United Arab Emirates, nulhaq@kfshrc.edu.sa.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23529273

Citation

Haq, Naveed, et al. "A Prospective Randomized Pilot Study On Intermittent Post-dialysis Dosing of Cinacalcet." International Urology and Nephrology, vol. 46, no. 1, 2014, pp. 113-9.
Haq N, Chaaban A, Gebran N, et al. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet. Int Urol Nephrol. 2014;46(1):113-9.
Haq, N., Chaaban, A., Gebran, N., Khan, I., Abbachi, F., Hassan, M., Bernsen, R., & Abouchacra, S. (2014). A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet. International Urology and Nephrology, 46(1), 113-9. https://doi.org/10.1007/s11255-013-0418-y
Haq N, et al. A Prospective Randomized Pilot Study On Intermittent Post-dialysis Dosing of Cinacalcet. Int Urol Nephrol. 2014;46(1):113-9. PubMed PMID: 23529273.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet. AU - Haq,Naveed, AU - Chaaban,Ahmed, AU - Gebran,Nicole, AU - Khan,Imran, AU - Abbachi,Fayez, AU - Hassan,Muhyeddin, AU - Bernsen,Roos, AU - Abouchacra,Samra, Y1 - 2013/03/26/ PY - 2012/10/23/received PY - 2013/03/13/accepted PY - 2013/3/27/entrez PY - 2013/3/27/pubmed PY - 2014/11/11/medline SP - 113 EP - 9 JF - International urology and nephrology JO - Int Urol Nephrol VL - 46 IS - 1 N2 - BACKGROUND: Treatment of secondary hyperparathyroidism (SHPT) is important in management of patients with end-stage renal disease on hemodialysis (HD). Calcimimetic agent, cinacalcet provides an option for control of SHPT in patients who fail traditional therapy. It may not have optimal results in non-compliant patients. To enhance compliance, we evaluated effectiveness of post-dialysis dosing of cinacalcet (group AD) as compared to daily home administration (group D) in a prospective randomized trial of HD patients with refractory SHPT. METHODS: After 2-week run-in phase, patients were randomly assigned to two treatment groups. In group AD (N = 12), patients were administered cinacalcet on the day of dialysis (3 times/week) by dialysis staff, while in control group D (N = 11), cinacalcet was prescribed daily to be taken by patients at home. Intact parathyroid hormone (i-PTH), serum calcium, phosphorus, and alkaline phosphatase were followed for 16 weeks and compared to baseline in both groups. Data were analyzed using between-groups linear regression for repeated measures. RESULTS: No significant decline in i-PTH occurred in group AD at 16 weeks as compared to a significant drop in group D (p = 0.006). However, subgroup analysis showed effectiveness of post-dialysis dosing in patients with less severe SHPT (p = 0.04). CONCLUSION: Although daily dosing overall was more effective for treatment of SHPT, dialysis dosing was effective in patients with less severe SHPT. This warrants a larger study considering the limitations of this pilot trial. In the meantime, dialysis dosing can be considered in non-compliant patients with less severe SHPT. SN - 1573-2584 UR - https://wwww.unboundmedicine.com/medline/citation/23529273/A_prospective_randomized_pilot_study_on_intermittent_post_dialysis_dosing_of_cinacalcet_ L2 - https://doi.org/10.1007/s11255-013-0418-y DB - PRIME DP - Unbound Medicine ER -